David E. Magee
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Bone health and osteoporosis research, Menopause: Health Impacts and Treatments, Endometriosis Research and Treatment, Endometrial and Cervical Cancer Treatments
Most-Cited Works
- → Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.(1994)612 cited
- → Structure−Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene(1997)175 cited
- → Environmental estrogens: Effects on cholesterol lowering and bone in the ovariectomized rat(1996)149 cited
- → Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators(1998)126 cited
- → Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats(1994)105 cited
- → The effects of raloxifene on tibia histomorphometry in ovariectomized rats.(1994)97 cited
- → Raloxifene is a Tissue‐Selective Agonist/Antagonist That Functions through the Estrogen Receptor(1995)87 cited
- → Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.(1996)74 cited
- → Effect of weight manipulation on bone loss due to ovariectomy and the protective effects of estrogen in the rat(1993)42 cited
- → Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats(1997)36 cited